title: Novelty-elicited mismatch negativity in patients with schizophrenia on admission and discharge.
abstract: OBJECTIVE
  Given recent reports of differences between mismatch negativity (MMN) elicited by always novel sounds (novelty-elicited MMN) and that elicited by repeated rare deviants (conventional MMN), we investigated novelty-elicited MMN and P3a in patients with schizophrenia before and after a nonstandardized inpatient treatment.
  
  
  METHODS
  Electrophysiological and clinical assessment of patients on admission and discharge from hospital. Assessment of control subjects on 2 sessions.
  
  
  METHODS
  Inpatient treatment in a psychiatric university hospital.
  
  
  METHODS
  20 patients with schizophrenia and 21 healthy control subjects of similar age and sex. Selection of patients with first- to third-episode schizophrenia.
  
  
  METHODS
  Early and late component MMN amplitudes and latencies, P3a amplitudes and latencies, Positive and Negative Syndrome Scale (PANSS), Global Assessment of Functioning (GAF), Extrapyramidal Symptom Scale (EPS), Abnormal Involuntary Movement Scale (AIMS) and chlorpromazine equivalents.
  
  
  RESULTS
  In patients with schizophrenia, novelty-elicited MMN was unimpaired on admission, and there was a statistically significant reduction of the late MMN component with treatment. Improvements in symptom expression were associated with increased latencies of the early MMN component.
  
  
  CONCLUSIONS
  Results indicate differences in information processing between conventional and novelty-elicited MMN. Some components of the novelty-elicited MMN might be more state dependent than those of the conventional MMN.
authors.affiliation: Clinic for Child and Adolescent Psychiatry and Psychotherapy, Technical University Aachen, Aachen, Germany.
authors.forename: I
authors.initials: I
authors.lastname: Grzella
authors.forename: B W
authors.initials: BW
authors.lastname: Müller
authors.forename: R D
authors.initials: RD
authors.lastname: Oades
authors.forename: S
authors.initials: S
authors.lastname: Bender
authors.forename: U
authors.initials: U
authors.lastname: Schall
authors.forename: D
authors.initials: D
authors.lastname: Zerbin
authors.forename: J
authors.initials: J
authors.lastname: Wolstein
authors.forename: G
authors.initials: G
authors.lastname: Sartory
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001143:Arousal / Q000187:drug effects / Q000502:physiology*; D001288:Attention / Q000187:drug effects / Q000502:physiology*; D002540:Cerebral Cortex / Q000187:drug effects / Q000503:physiopathology; D003265:Contingent Negative Variation / Q000187:drug effects / Q000502:physiology*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D010343:Patient Admission; D010351:Patient Discharge; D011569:Psychiatric Status Rating Scales; D011930:Reaction Time / Q000187:drug effects / Q000502:physiology; D012559:Schizophrenia / Q000188:drug therapy / Q000503:physiopathology*
chemical_list: D014150:Antipsychotic Agents